Want to join the conversation?
$MYL announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of $CELG's Vidaza Injection, 100 mg/vial. Azacitidine for Injection is nucleoside metabolic inhibitor indicated for treatment of 5 French-American-British (FAB) subtypes of myelodysplastic syndrome, blood cell disorder occur for cancer treatments.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.